Opinion: Do Americans expect too much from drugs?
A magic drug just got a little more magical on Monday, when a pill version of Wegovy, Novo Nordisk’s GLP-1 for weight loss, arrived in pharmacies nationwide. Previously only available by injection, everyone seems thrilled about the new pill — patients, physicians, and particularly investors, who have sent shares of Novo Nordisk up 15% since […]
Pharmaceutics, Vol. 18, Pages 81: Ketamine in Diabetes Care: Metabolic Insights and Clinical Applications
Pharmaceutics, Vol. 18, Pages 81: Ketamine in Diabetes Care: Metabolic Insights and Clinical Applications Pharmaceutics doi: 10.3390/pharmaceutics18010081 Authors: Shiryn D. Sukhram Majandra Sanchez Ayotunde Anidugbe Bora Kupa Vincent P. Edwards Muhammad Zia Grozdena Yilmaz Background: Depression and diabetic neuropathy (DN) commonly complicate diabetes and impair glycemic control and quality of life. Ketamine and its S-enantiomer, […]
Trump’s ‘beautiful’ new law means states have big decisions this year on Medicaid, SNAP and taxes
President Donald Trump listens as Centers for Medicare & Medicaid Services administrator Dr. Mehmet Oz speaks during an executive order signing in the Oval Office of the White House, Thursday, Dec. 18, 2025, in Washington. (AP Photo/Evan Vucci) 2026-01-08T06:07:56Z States have major decisions to make in 2026 about the social safety net and taxes in […]
The problem with blaming everything on inflammation
Chronic inflammation is a modern health problem — one that too many wellness influencers oversimplify. Inflammation is on everybody’s minds these days, and it seems like wherever you look, someone is telling you how to reduce your inflammation, from influencers on your TikTok feed or Instagram reels to even US Health Secretary Robert F. Kennedy Jr. […]
Brave new world: Making pizzas in the era of the GLP-1 phenomenon
IJMS, Vol. 27, Pages 627: KBN2202 Suppresses Gonadal White Adipose Tissue Expansion in Female Mice Fed a High-Fat Diet
IJMS, Vol. 27, Pages 627: KBN2202 Suppresses Gonadal White Adipose Tissue Expansion in Female Mice Fed a High-Fat Diet International Journal of Molecular Sciences doi: 10.3390/ijms27020627 Authors: Moonhang Kim Jeong-Hyeon Heo Seok Hwan Chang Sun-Young Lee Jihun Kim Moon-Geun Shin Jong Sung Kim Mi Ran Choi Sang-Rae Lee Obesity treatments increasingly target multiple pathways beyond […]
Top Insulin Expert: Insulin Is More Dangerous Than Sugar! This Will Strip Fat Faster Than Anything!
No.1 Health Doctor Benjamin Bikman breaks down keto, insulin resistance, sugar addiction, and calorie counting, and the ONE test that predicts weight gain! Dr Benjamin Bikman is a metabolic scientist and researcher focused on the link between insulin resistance and chronic disease. He is Professor of Cell Biology at Brigham Young University and Co-founder of […]
Nutrition Strategies for Next‐Generation Incretin Therapies: A Systematic Scoping Review of the Current Evidence
ABSTRACT Next-generation incretin therapies, including semaglutide and tirzepatide, have transformed obesity and Type 2 diabetes management. However, evidence-based nutritional strategies to support safe and effective use of these agents remain limited. To address this gap, we conducted a systematic scoping review across five databases of studies published between January 2015 and April 2025 to map […]
Study highlights prevalence of GLP-1/GIP medication use for weight loss in UK
In early 2025, around 4.9 million British adults – almost one in ten – are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The findings, which are based on a nationally representative household survey of 5,260 British […]
The Executive Briefing: Saks in Crisis; The Battle for Lululemon; A Holiday Shopping Miracle
America’s largest department store operator is on the brink, Lululemon’s founder is making moves and GLP-1 pills promise to shake up fashion this year. Read on for your concise breakdown of November’s key developments from executive editor Brian Baskin.